After reviewing this study, Anton Bilchik, MD, PhD, surgical oncologist, chief of medicine, and director of the Gastrointestinal and Hepatobiliary Program at Providence Saint Johns Cancer Institute in Santa Monica, CA, not involved in the research, told MNT this was one of the most provocative, interesting studies he has seen in a long time simply because there has been an explosion of interest and use of GLP-1 agonist drugs such as Ozempic and Mounjaro
Statements Author contributions TD: Conceptualization, Investigation, Data curation, Visualization, Writingoriginal draft, Writingreview and editing
Without a bat of an eye, they turned up the heat on the defense for the best possible outcome for all parties
Troubleshooting Common Dosing Challenges Even with careful planning, researchers may encounter challenges when implementing KLOW blend peptide protocols
You may feel mild stinging during injections, but discomfort is minimal and short-lived
The P/E is now 35x